Compare SCL & MNKD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SCL | MNKD |
|---|---|---|
| Founded | 1932 | 1991 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Package Goods/Cosmetics | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.3B | 1.2B |
| IPO Year | 1994 | 2004 |
| Metric | SCL | MNKD |
|---|---|---|
| Price | $63.42 | $4.06 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 1 | 8 |
| Target Price | ★ $75.00 | $8.69 |
| AVG Volume (30 Days) | 80.4K | ★ 3.5M |
| Earning Date | 04-28-2026 | 05-06-2026 |
| Dividend Yield | ★ 3.23% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $1,803,737,000.00 | $348,966,000.00 |
| Revenue This Year | $6.60 | $35.81 |
| Revenue Next Year | $5.27 | $11.89 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ 22.23 |
| 52 Week Low | $41.82 | $2.23 |
| 52 Week High | $68.00 | $6.51 |
| Indicator | SCL | MNKD |
|---|---|---|
| Relative Strength Index (RSI) | 50.71 | 49.95 |
| Support Level | $49.36 | $3.74 |
| Resistance Level | $66.33 | $4.23 |
| Average True Range (ATR) | 1.54 | 0.15 |
| MACD | -0.42 | -0.01 |
| Stochastic Oscillator | 39.89 | 35.40 |
Stepan Co manufactures and sells a variety of chemicals and chemical-based products. The company organizes itself into three segments based on product type. The surfactants segment, which generates the majority of revenue, sells cleaning agents used in detergents, shampoos, body wash, fabric softeners, toothpastes, and other personal-care products. The polymers segment sells polyurethane used to manufacture rigid foam for thermal insulation, as well as phthalic anhydride used to make plastic components for the construction, automotive, and boating industries. The specialty products segment sells chemicals used in food and flavoring. The majority of Stepan's revenue comes from the United States, followed by France, Poland, the United Kingdom, Brazil, Mexico, and other countries.
MannKind Corp is a biopharmaceutical company focused on the development and commercialization of patient-centric therapies that address serious unmet medical needs for those living with cardiometabolic and orphan lung diseases. The Company is currently commercializing three products: Afrezza (insulin human) Inhalation Powder, an ultra rapid-acting inhaled insulin indicated to improve glycemic control in adults with diabetes; Furoscix (furosemide injection), to treat fluid buildup in patients with chronic heart failure or chronic kidney disease; and the V-Go wearable insulin delivery device, which provides continuous subcutaneous infusion of insulin in adults that require insulin.